The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Terry-Ann Burrell net worth and biography

Terry-Ann Burrell Biography and Net Worth

CFO of Beam Therapeutics

Terry-Ann Burrell has served as our Chief Financial Officer since August 2019 and as our Chief Financial Officer and Treasurer since September 2019. From May 2008 to August 2019, Ms. Burrell worked at J.P. Morgan Securities LLC, where she most recently served as Managing Director. Ms. Burrell was responsible for deal execution across both mergers and acquisitions and capital markets. In her role, she advised biotechnology and pharmaceutical companies on strategic considerations, including mergers and acquisitions, initial public and secondary offerings and valuation analysis. Ms. Burrell currently serves on the board of directors of Recursion Pharma, a biotherapeutics company. Ms. Burrell holds a bachelor’s degree from Harvard College and an MBA from New York University’s Leonard N. Stern School of Business. Provided by Tagnifi.

What is Terry-Ann Burrell's net worth?: The estimated net worth of Terry-Ann Burrell is at least $1.76 million as of April 1st, 2024. Ms. Burrell owns 70,137 shares of Beam Therapeutics stock worth more than $1,756,932 as of November 23rd. This net worth estimate does not reflect any other investments that Ms. Burrell may own. Learn More about Terry-Ann Burrell's net worth.
How do I contact Terry-Ann Burrell?: The corporate mailing address for Ms. Burrell and other Beam Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Beam Therapeutics can also be reached via phone at 857-327-8775 and via email at [email protected]. Learn More on Terry-Ann Burrell's contact information.
Has Terry-Ann Burrell been buying or selling shares of Beam Therapeutics?: Terry-Ann Burrell has not been actively trading shares of Beam Therapeutics in the last ninety days. Most recently, Terry-Ann Burrell sold 5,446 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $32.12, for a transaction totalling $174,925.52. Following the completion of the sale, the chief financial officer now directly owns 70,137 shares of the company's stock, valued at $2,252,800.44. Learn More on Terry-Ann Burrell's trading history.
Who are Beam Therapeutics' active insiders?: Beam Therapeutics' insider roster includes Terry-Ann Burrell (CFO), Giuseppe Ciaramella (Insider), Graham Cooper (Director), John Evans (CEO), and John Evans (CEO). Learn More on Beam Therapeutics' active insiders.
Are insiders buying or selling shares of Beam Therapeutics?: In the last twelve months, insiders at the sold shares 15 times. They sold a total of 382,107 shares worth more than $10,445,723.95. The most recent insider tranaction occured on November, 6th when President Giuseppe Ciaramella sold 51,110 shares worth more than $1,347,259.60. Insiders at Beam Therapeutics own 4.2% of the company. Learn More about insider trades at Beam Therapeutics.
Information on this page was last updated on 11/6/2024.

Terry-Ann Burrell Insider Trading History at Beam Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2024	Sell	5,446	$32.12	$174,925.52	70,137
4/3/2023	Sell	2,454	$30.31	$74,380.74	49,303
1/26/2023	Sell	1,102	$45.16	$49,766.32	31,277
1/24/2023	Sell	14,810	$45.01	$666,598.10	31,277
1/18/2023	Sell	47,195	$45.14	$2,130,382.30	31,277
3/31/2022	Sell	1,787	$59.11	$105,629.57	38,278
6/30/2021	Sell	30,000	$122.00	$3,660,000.00
6/28/2021	Sell	45,000	$107.69	$4,846,050.00	69,809

Terry-Ann Burrell Buying and Selling Activity at Beam Therapeutics

Beam Therapeutics Company Overview

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Today's Range

Now: $25.05

$23.18

$25.43

50 Day Range

MA: $24.54

$21.55

$30.35

2 Week Range

Now: $25.05

$20.84

$49.50

Volume

1,184,461 shs

Average Volume

1,235,536 shs

Market Capitalization

$2.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Financial Prophecy

From Porter & Company | Ad